Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Stock Chart & Stats
$5.36
$0.18(4.59%)
At close: 4:00 PM EST
$5.36
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.41 - $7.37
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.14M
Market Cap
$417.60M
Enterprise Value$368.35M
Total Cash (Recent Filing)$236.14M
Total Debt (Recent Filing)$21.94M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 18, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding77,910,240
10 Day Avg. Volume1,227,827
30 Day Avg. Volume1,142,615
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-464.51
Enterprise Value/Ebitda-2.23
Forecast
1Y Price Target
$14.25Price Target Upside165.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe expected share price return is 217.5%.
Licensing And CollaborationSolid Biosciences announced a licensing agreement with Andelyn Biosciences for AAV-SLB101, which is seen as a validation of its product's safety and muscle-targeted capabilities.
Regulatory AdvancementThe granting of the Innovation Passport is a meaningful achievement that should boost regulatory engagement and accelerate SGT-003’s development timeline in the U.K.
Bears Say
Data VariabilityMean microdystrophin expression at Day 90 was 58%, impacted by three outliers in the data.
Regulatory DelaysSLDB shares may come under pressure with the FDA meeting timeline moving into 1H26.
Therapeutic PerformanceThree of the ten evaluable patients showed suboptimal micro-dystrophin expression, which lowered the overall average.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.41 and its highest was $7.37 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $417.60M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Mar 18, 2026 which is in 110 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Nov 06, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.439 by -$0.041.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.51.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 77,910,240 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.439. Following the earnings report the stock price went up 7.379%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
Solid Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
400.92% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (165.86% Upside)
$14.25 (165.86% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 73.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.26%
12-Months-Change
Fundamentals
Return on Equity
-86.83%
Trailing 12-Months
Asset Growth
29.31%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$14.25
▲(165.86% Upside)
Technical Analysis
Autolus Therapeutics
―
Korro Bio
―
ADC Therapeutics
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Ownership Overview
34.05% Insiders
11.64% Mutual Funds
12.60% Other Institutional Investors
34.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---